Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
CanSino Biologics Inc.’s single-dose Covid-19 vaccine – given at a lower dosage than that for adults – is safe and triggers an immune response in children aged 6-17, results from a small trial showed.
The body of real-world evidence around Covid-19 continues to build, and a study released Aug. 26 in The Lancet points to concerning long-term effects for hospital survivors at the one-year mark.
RegeneRx Biopharmaceuticals Inc. announced that a multi-institutional team of scientists from eight American research centers published a research paper on new therapeutic approaches for Covid-19 in which they propose that Thymosin beta 4 (Tβ4), because of its ability to induce fibrinolysis, among other activities, may be useful in treating patients with the Covid-19 virus.
